Now Reading
British pharmaceutical hopes US agency to approve epilepsy drug next month

British pharmaceutical hopes US agency to approve epilepsy drug next month

PuffPuffPost Team
Autism In Children Improved By 80% With CBD Oil Therapy

The British GW Pharmaceuticals is set to launch a potential mega-hit drug that treats severe forms of epilepsy.

CEO of the Nasdaq-listed GW Justin Gover said product approval of the cannabis-based Epidiolex would show that cannabis research is “serious science”.

“This type of medicine and these classes of medicines could become important drugs across a range of other disease areas.”

If Epidiolex is approved, GW is hoping to launch the medicine in Britain and Europe next year, LA Times reported.

The research and development of the drug are done in Cambridge, UK. However, the green herb is produced and processed at a secret location in England so it does not attract unwanted attention.

See Also
wp pic corporations - British pharmaceutical hopes US agency to approve epilepsy drug next month

Regulatory approval in the US cements a significant breakthrough for the company. After many setbacks, they would enter the realm of progress.

GWs CEO Justin Gover Image via Business Weekly - British pharmaceutical hopes US agency to approve epilepsy drug next month
GWs CEO Justin Gover (Image via Business Weekly)

GW is a $4.5 billion company with shares that go as high as $13.

[share-btn]
Comments
Scroll To Top